Oportun Reports First Quarter 2024 Financial Results
Strong performance versus guidance Total operating expenses declined 15% sequentially and 25% year-over-year GAAP net loss sharply reduced by $76M […]
Cipher Mining to Participate in the 19th Annual Needham Technology, Media, & Consumer Conference
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”), a U.S.-based Bitcoin […]
Montauk Renewables Announces First Quarter 2024 Results
PITTSBURGH, May 09, 2024 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company […]
NI Holdings, Inc. Reports Results for First Quarter Ended March 31, 2024
FARGO, N.D., May 09, 2024 (GLOBE NEWSWIRE) — NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended […]
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data […]
DoubleDown Interactive to Participate at 19th Annual Needham Technology, Media & Consumer Conference on May 16
SEATTLE, May 09, 2024 (GLOBE NEWSWIRE) — DoubleDown Interactive (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher […]
Tyson Foods Announces Quarterly Dividend
SPRINGDALE, Ark., May 09, 2024 (GLOBE NEWSWIRE) — The Board of Directors of Tyson Foods (NYSE: TSN), at a meeting […]
ESCO Reports Second Quarter Fiscal 2024 Results
St. Louis, May 09, 2024 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its […]
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly […]
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with […]
